Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 6/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27570602 | 0.83 | ALOX5 (0.45) | CCNE1CDK2CDK5ALOX5TSHR | |
| SCHEMBL27551074 | 0.80 | CDK2 (0.38) | CCNE1CDK2CDK5ALOX5ALDH1A1 | |
| SCHEMBL6710785 | 0.80 | ALOX5 (0.39) | CCNE1CDK2CDK5ALOX5ALDH1A1 | |
| SCHEMBL7257382 | 0.76 | ADORA3 (0.50) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL6713415 | 0.76 | CCNE1 (0.35) | CCNE1CDK2CDK5ALOX5ALDH1A1 | |
| SCHEMBL6712266 | 0.76 | CCNE1 (0.35) | CCNE1CDK2CDK5ALOX5TSHR | |
| SCHEMBL6711707 | 0.76 | MLYCD (0.47) | CCNE1CDK2CDK5ALOX5ALDH1A1 | |
| SCHEMBL27574281 | 0.75 | CDK2 (0.38) | CCNE1CDK2CDK5ALOX5TSHR | |
| SCHEMBL7257113 | 0.75 | CDK2 (0.38) | CCNE1CDK2CDK5ALOX5ALDH1A1 | |
| SCHEMBL7848231 | 0.75 | CCNE1 (0.38) | CCNE1CDK2CDK5ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1325390-A | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | claimed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| CN-1325390-A | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CCNE1 83/4885CDK2 3/4885CDK5 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.